Bank of New York Mellon
DSGN icon

Bank of New York Mellon’s Design Therapeutics DSGN Stock Holding History

Bank of New York Mellon’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.33M Buy
92,069
+12,424
+16% +$155K ﹤0.01% 3195
2026
Q1 		$847K Sell
79,645
-5,330
-6% -$53.9K ﹤0.01% 3310
2025
Q4 		$797K Sell
84,975
-2,500
-3% -$19.6K ﹤0.01% 3369
2025
Q3 		$659K Sell
87,475
-7,128
-8% -$35.7K ﹤0.01% 3441
2025
Q2 		$319K Sell
94,603
-745
-0.8% -$2.79K ﹤0.01% 3764
2025
Q1 		$368K Hold
95,348
– – ﹤0.01% 3607
2024
Q4 		$588K Sell
95,348
-3,777
-4% -$21.9K ﹤0.01% 3437
2024
Q3 		$533K Sell
99,125
-18,985
-16% -$89.3K ﹤0.01% 3486
2024
Q2 		$396K Buy
118,110
+2,868
+2% +$11.2K ﹤0.01% 3694
2024
Q1 		$464K Sell
115,242
-5,550
-5% -$14.8K ﹤0.01% 3567
2023
Q4 		$320K Hold
120,792
– – ﹤0.01% 3769
2023
Q3 		$285K Sell
120,792
-1,873
-2% -$8.74K ﹤0.01% 3819
2023
Q2 		$773K Sell
122,665
-1,388
-1% -$8.49K ﹤0.01% 3360
2023
Q1 		$716K Sell
124,053
-2,431
-2% -$18.2K ﹤0.01% 3297
2022
Q4 		$1.3M Buy
126,484
+1,277
+1% +$17.3K ﹤0.01% 3070
2022
Q3 		$2.09M Buy
125,207
+22,823
+22% +$454K ﹤0.01% 2817
2022
Q2 		$1.43M Buy
102,384
+12,428
+14% +$168K ﹤0.01% 3018
2022
Q1 		$1.45M Buy
89,956
+22,848
+34% +$350K ﹤0.01% 3101
2021
Q4 		$1.44M Buy
67,108
+30,632
+84% +$526K ﹤0.01% 3175
2021
Q3 		$536K Buy
36,476
+2,979
+9% +$49.5K ﹤0.01% 3772
2021
Q2 		$666K Buy
+33,497
New +$845K ﹤0.01% 3634

Other funds holding DSGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
OC
Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AA
AlphaCentric Advisors San Juan, Puerto Rico $118M AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of New York Mellon's DSGN Position: Q2 2026 in Review

Bank of New York Mellon increased its Design Therapeutics (DSGN) stake by 16% in Q2 2026, buying an estimated $155K and bringing the position to 92,069 shares worth $1.33M. The position accounts for ﹤0.01% of the portfolio, ranked #3195.

Bank of New York Mellon first reported a position in DSGN in Q2 2021 and has held it in 21 quarters since. The position peaked at $2.09M in Q3 2022. 39 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Bank of New York Mellon held 92,069 shares of Design Therapeutics worth $1.33M as of Q2 2026.
  • Bank of New York Mellon bought 12,424 Design Therapeutics shares in Q2 2026, an estimated $155K.
  • Design Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3195 holding.
  • Bank of New York Mellon first reported a position in Design Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • Bank of New York Mellon's Design Therapeutics position peaked at $2.09M in Q3 2022.
  • 39 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.